Douglas Pharma Of New Zealand Gets U.S. Approval For Acne Drug
This article was originally published in PharmAsia News
Executive Summary
New Zealand’s Douglas Pharmaceuticals said its Myorisan (isotretinoin) acne drug has received marketing clearance in the U.S. where the market is estimated to be worth $400 million.